Previous 10 | Next 10 |
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences in September: H.C. Wainwright & Co. Ann...
Urogen Pharma Ltd (URGN) Q2 2022 Earnings Conference Call August 11, 2022, 10:00 ET Company Participants Vincent Perrone - Senior Director, IR Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer Jeffrey Bova - Chief Comme...
UroGen Pharma press release ( NASDAQ: URGN ): Q2 GAAP EPS of -$1.18 beats by $0.12 . Revenue of $16.6M (+27.4% Y/Y) misses by $0.68M . The company reaffirmed 2022 full-year revenue guidance of $70-$80 million vs consensus of $75.21M For further details se...
Reported Jelmyto® net product revenue of $16.6 million, a 22% increase from the first quarter of 2022, and 28% increase YoY; reaffirmed 2022 full-year revenue guidance of $70-$80 million Enrollment of UGN-102 Phase 3 single-arm, ENVISION pivotal trial in subjects with low...
Conference Call and Webcast Scheduled for Thursday, August 11, 2022 at 10:00 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will ...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences: H.C. Wainwright & Co. Global Investmen...
-- Multi-Center Retrospective Study was Presented at the 2022 American Urological Association Annual Meeting in New Orleans -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today highli...
New data on in-office nephrostomy tube administration of JELMYTO® (mitomycin) for pyelocalyceal solution, the only non-surgical, kidney-sparing treatment for adults with low-grade upper tract urothelial cancer Results from the Phase 2b OPTIMA II trial of UGN-102 and imp...
UroGen Pharma Ltd. (URGN) Q1 2022 Earnings Conference Call May 10, 2022, 10:00 AM ET Company Participants Vincent Perrone - Senior Director of IR Liz Barrett - President and CEO Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer Don Kim - CFO Conference Call Particip...
UroGen Pharma press release (NASDAQ:URGN): Q1 GAAP EPS of -$1.25 beats by $0.09. Revenue of $13.56M (+81.0% Y/Y) misses by $1.62M. For further details see: UroGen Pharma GAAP EPS of -$1.25 beats by $0.09, revenue of $13.56M misses by $1.62M
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...